QUANTITATIVE-ANALYSIS OF MUTANT P53 PROTEIN IN BREAST-TUMOR CYTOSOLS AND STUDY OF ITS ASSOCIATION WITH OTHER BIOCHEMICAL PROGNOSTIC INDICATORS IN BREAST-CANCER

被引:15
作者
LEVESQUE, MA
DIAMANDIS, EP
YU, H
SUTHERLAND, DJA
机构
[1] TORONTO HOSP,DEPT CLIN BIOCHEM,TORONTO WESTERN DIV,TORONTO M5T 2S8,ON,CANADA
[2] UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1L5,ON,CANADA
[3] UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,TORONTO BAYVIEW REG CANC CTR,TORONTO M4N 3M5,ON,CANADA
关键词
P53 TUMOR SUPPRESSOR GENE; PROGNOSTIC INDICATORS IN BREAST CANCER; PROSTATE SPECIFIC ANTIGEN IN BREAST CANCER; CARCINOEMBRYONIC ANTIGEN;
D O I
10.1007/BF00666062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast tumors are thought to originate, grow, and metastasize in an environment which includes steroid hormone receptors, their cognate steroid ligands, and many gene products which are regulated by steroid hormone receptor-ligand complexes. In this paper we describe highly sensitive and quantitative immunofluorometric procedures for measuring three proteins that are candidate prognostic indicators in breast cancer, namely, the p53 tumor suppressor gene product, carcinoembryonic antigen (CEA), and prostate specific antigen (PSA). These proteins were quantified in over 950 cytosolic tumor extracts along with estrogen and progesterone receptors (ER, PR). Association analysis between all five biochemical parameters revealed strong negative associations between p53 and receptors and strong positive associations between CEA and receptors. Negative associations between p53 and CEA and between CEA and PSA were also found. These associations, not quantitatively studied in previous reports, are related to each other using a hypothetical model. The observed associations may further contribute to the understanding of the biology of breast tumors.
引用
收藏
页码:179 / 195
页数:17
相关论文
共 73 条
[1]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[2]  
BARNES R, 1991, AM J PATHOL, V139, P245
[3]  
BARTEK J, 1991, ONCOGENE, V6, P1699
[4]   PATTERNS OF EXPRESSION OF THE P53 TUMOR SUPPRESSOR IN HUMAN BREAST TISSUES AND TUMORS INSITU AND INVITRO [J].
BARTEK, J ;
BARTKOVA, J ;
VOJTESEK, B ;
STASKOVA, Z ;
REJTHAR, A ;
KOVARIK, J ;
LANE, DP .
INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (05) :839-844
[5]   A DOUBLE MONOCLONAL TIME-RESOLVED IMMUNOFLUOROMETRIC ASSAY OF CARCINOEMBRYONIC ANTIGEN IN SERUM [J].
BHAYANA, V ;
DIAMANDIS, EP .
CLINICAL BIOCHEMISTRY, 1989, 22 (06) :433-438
[6]   ABNORMAL P53 IMMUNOREACTIVITY AND PROGNOSIS IN NODE-NEGATIVE BREAST CARCINOMAS WITH LONG-TERM FOLLOW-UP [J].
BOSARI, S ;
LEE, AKC ;
VIALE, G ;
HEATLEY, GJ ;
COGGI, G .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1992, 421 (04) :291-295
[7]   P53 MUTATIONS, ANOTHER BREAST-CANCER PROGNOSTIC FACTOR [J].
CALLAHAN, R .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (11) :826-827
[8]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[9]  
2-H
[10]   LOSS OF HETEROZYGOSITY ON THE SHORT ARM OF CHROMOSOME-17 IS ASSOCIATED WITH HIGH PROLIFERATIVE CAPACITY AND DNA ANEUPLOIDY IN PRIMARY HUMAN BREAST-CANCER [J].
CHEN, LC ;
NEUBAUER, A ;
KURISU, W ;
WALDMAN, FM ;
LJUNG, BM ;
GOODSON, W ;
GOLDMAN, ES ;
MOORE, D ;
BALAZS, M ;
LIU, E ;
MAYALL, BH ;
SMITH, HS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (09) :3847-3851